Scott Shields Emerson

{{Orphan|date=November 2022}}

{{Infobox person

| name = Scott Shields Emerson

| citizenship = American

| education = University of Virginia
and University of Washington

| occupation = Professor of biostatistics

| title = Emeritus professor of the University of Washington

}}

Scott Shields Emerson is an American biostatistician and emeritus professor of the University of Washington.{{Cite web|url=https://www.statnews.com/2021/06/08/fda-expert-panel-resigns-alzheimers-approval/|title=Member of FDA's expert panel resigns over controversial Alzheimer's therapy approval|first=Andrew|last=Joseph|date=June 8, 2021}}{{Cite web|url=https://www.medpagetoday.com/neurology/alzheimersdisease/97839|title=Aducanumab Data Finally Published, but Alzheimer's Experts Spot Problems|date=March 23, 2022|website=www.medpagetoday.com}}

Emerson was a professor of biostatistics{{Cite magazine|url=https://time.com/5908589/alzheimers-drug-biogen-fda-committee/|title=FDA Committee Expresses Concerns about Promising Alzheimer's Drug|magazine=Time}} at the University of Washington in the School of Public Health's department of biostatistics{{Cite web|url=http://www.uwintrostats.org/index.asp|title=Emerson Statistics | R information|website=www.uwintrostats.org}} from 1999{{cite web|url=http://www.emersonstatistics.com/dnlds/semerson.pdf|title=Curriculum Vitae|author= Scott Shields Emerson |website=emersonstatistics.com}} to 2017.{{Cite web|url=https://faculty.washington.edu/semerson/|title=Scott S. Emerson, M.D., Ph.D. | Home Page|website=faculty.washington.edu}}{{Cite web|url=https://sph.washington.edu/faculty/facbio/Emerson_Scott|title=| UW School of Public Health|website=sph.washington.edu}} Emerson worked on randomized controlled trial design.{{Cite journal|title=Frequentist evaluation of group sequential clinical trial designs|first1=Scott S.|last1=Emerson|first2=John M.|last2=Kittelson|first3=Daniel L.|last3=Gillen|date=December 10, 2007|journal=Statistics in Medicine|volume=26|issue=28|pages=5047–5080|doi=10.1002/sim.2901|pmid=17573678 |s2cid=16825572 |doi-access=free}}{{Cite web|url=http://rctdesign.org/Welcome.html|title=RCTdesign.org : Methods and Software for Clinical Trials|website=rctdesign.org}} Emerson has been part of advisory committees for the Food and Drug Administration,{{Cite web|url=https://www.alzforum.org/news/community-news/advisory-committee-again-urges-fda-vote-no-aducanumab|title=Advisory Committee Again Urges FDA to Vote No on Aducanumab | ALZFORUM|website=www.alzforum.org}}{{Cite web|url=https://www.axios.com/2021/07/27/biogen-jama-aduhelm-clinical-trial-results-publish|title=Biogen pulled Aduhelm paper after JAMA demanded edits|first=Bob|last=Herman|date=July 27, 2021|website=Axios}} including on work related to Aduhelm.{{Cite web|url=https://www.biospace.com/article/biogen-withdraws-aduhelm-clinical-trial-paper-from-jama/|title=JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy|website=BioSpace}}{{Cite web|url=https://www.theregreview.org/2021/07/06/heled-rutschman-vertinsky-regulatory-reactivity-fda-approval-aduhelm/|title=Regulatory Reactivity in FDA's Approval of Aduhelm | The Regulatory Review|first=The Regulatory|last=Review|date=July 6, 2021|website=www.theregreview.org}}